Samsung Medison Expands Women’s Health Diagnostic Portfolio With Launch of Premium Ultrasound ‘HERA Z10’

Samsung Medison launched its premium obstetrics and gynecology (OB/GYN) ultrasound diagnostic system, the HERA Z10. Alongside the flagship HERA Z20, the new system officially completes the HERA Z Series (Z20 & Z10) lineup. With global trends showing an increase in maternal age and pregnancy-related complications, precision imaging for prenatal diagnostics and rapid clinical decision-making have […]

Heart Health Supplements Market Trends Influencing Consumer Choices in 2026

The global heart health supplements market was valued at USD 10.3 billion in 2025 and is expected to reach USD 10.8 billion in 2026. By 2033, the [read full press release...]

A Closer Look at the Global Fertility Testing Devices Market

Reproductive health is no longer a topic confined to clinics — it’s moving into homes, apps, and wearables. As more couples delay parenthood and infertility [read full press release...]

What’s Fueling the Boom in the Gluten-Free Products Market?

Once a niche category limited to specialty health stores, gluten-free food has moved firmly into the mainstream. Supermarket aisles, restaurant menus, and e-commerce platforms now [read full press release...]

CART Blood Pressure Monitor Demonstrates Utility in BP Monitoring for AF and Heart Failure Patients

- First to demonstrate clinical utility of ring-type BP monitoring in AF and heart failure patients - Highlighted CART blood pressure monitor's multifaceted value, including ESH-based validation and sleep apnea tracking MUNICH and SEOUL, South Korea, Sept. 7, 2026 /PRNewswire/ -- Sky Labs...

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

(PR-inside.com) The shares so repurchased will be cancelled or held as treasury shares. Taking concrete action to respond to market concerns, this repurchases plan demonstrates management's unwavering confidence in the company's intrinsic value. The plan has come into effect and will be implemented as soon as practicable. As a continuation of the Group's long-term value management toolkit, the company will dynamically evaluate and execute repurchases on a rolling basis in response to market conditions, establishing a normalized mechanism for shareholder returns. In the first half of 2026, Fosun Pharma's earnings quality continued to improve, with revenue contributions from innovative drugs and international ..

World-first International Standard launched as demand grows for better workplace support during menstruation and menopause

GENEVA, Sept. 7, 2026 /PRNewswire/ -- The International Organization for Standardization (ISO) has today launched ISO 45010 - Occupational health and safety management — Menstruation and menopause in the workplace — Guidance, the world's first International Standard providing guidance to...

Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs

HONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong Limited (the "HK Stock Exchange"), have been included in the list of eligible securities...

Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction

Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company,...

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust...

International Students Ready Themselves for Yoga Teacher Training in India

October 20, 2026 Deadline Approaching: Join Class Action Against Fractyl ...

(PR-inside.com) NEW YORK, NY / ACCESS Newswire / September 6, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ:GUTS) securities. If you suffered a loss on your Fractyl Health, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Fractyl Health, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against ..